2023
Anti-Müllerian Hormone Level Decline in Patients Undergoing Hysterectomy With and Without Oophorectomy Compared With Natural Menopause
Santoro N, Flyckt R, Davis A, Finkelstein J, Crawford S, Sun F, Derby C, Morrison A, Sluss P, Zhang H. Anti-Müllerian Hormone Level Decline in Patients Undergoing Hysterectomy With and Without Oophorectomy Compared With Natural Menopause. Obstetrics And Gynecology 2023, 141: 331-340. PMID: 36649324, PMCID: PMC9858351, DOI: 10.1097/aog.0000000000005049.Peer-Reviewed Original ResearchConceptsFinal menstrual periodAnti-Müllerian hormone levelsAMH levelsNatural menopauseHormone levelsUndetectable AMH levelsCommunity-based studyOvarian conservationOvarian reserveAMH measurementOvarian failureMenstrual periodSurgery dateHysterectomyLinear mixed modelingMenopauseSurvival analysisPatientsImmediate reductionMixed modelingWomenOvariesSimilar patternRapid declineBSO
2019
Lower antimüllerian hormone is associated with lower oocyte yield but not live-birth rate among women with obesity
Vitek W, Sun F, Baker VL, Styer AK, Christianson MS, Stern JE, Zhang H, Polotsky AJ. Lower antimüllerian hormone is associated with lower oocyte yield but not live-birth rate among women with obesity. American Journal Of Obstetrics And Gynecology 2019, 222: 363.e1-363.e7. PMID: 31589862, PMCID: PMC8022853, DOI: 10.1016/j.ajog.2019.09.046.Peer-Reviewed Original ResearchConceptsNormal body mass indexAntimüllerian hormone levelsLower antimüllerian hormoneBody mass indexLower oocyte yieldLive birth rateAntimüllerian hormoneLow ovarian reserveOocyte yieldMass indexHormone levelsOvarian reserveBody mass index 18.5Low antimüllerian hormone levelsAssisted Reproductive Technology Clinic Outcome Reporting System databaseLower live birth ratesClass 3 obesitySerum antimüllerian hormoneClass 1 obesityClass 2 obesityNumber of oocytesSmall antral folliclesReporting System databaseNormal BMIRetrospective cohort
2017
Association of uterine fibroids and pregnancy outcomes after ovarian stimulation–intrauterine insemination for unexplained infertility
Styer AK, Jin S, Liu D, Wang B, Polotsky AJ, Christianson MS, Vitek W, Engmann L, Hansen K, Wild R, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Christy A, Diamond MP, Eisenberg E, Zhang H, Santoro N, Network I. Association of uterine fibroids and pregnancy outcomes after ovarian stimulation–intrauterine insemination for unexplained infertility. Fertility And Sterility 2017, 107: 756-762.e3. PMID: 28089575, PMCID: PMC5472203, DOI: 10.1016/j.fertnstert.2016.12.012.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, SpontaneousAdultBlack or African AmericanDrug Therapy, CombinationFemaleFertilityFertility AgentsHumansInfertilityInsemination, ArtificialLeiomyomaLive BirthOvulationOvulation InductionPregnancyPregnancy RatePregnancy TestsProspective StudiesRisk FactorsTreatment OutcomeUnited StatesUterine NeoplasmsConceptsUnexplained infertilityUterine fibroidsPregnancy outcomesClinical trialsSerum antimüllerian hormone levelsBirth rateNon-African American womenGreater uterine volumeMultiple Intrauterine GestationsNormal uterine cavityClinical pregnancy rateAntimüllerian hormone levelsMulticenter clinical trialAmerican womenAfrican American womenClinical pregnancyIntrauterine gestationUterine volumeConception cyclesUterine cavityPregnancy lossHormone levelsPregnancy rateAntral folliclesMAIN OUTCOME
2015
Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics
Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Ager J, Huang H, Hansen KR, Baker V, Usadi R, Seungdamrong A, Bates GW, Rosen RM, Haisonleder D, Krawetz SA, Barnhart K, Trussell JC, Jin Y, Santoro N, Eisenberg E, Zhang H, Network I. Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics. Fertility And Sterility 2015, 103: 962-973.e4. PMID: 25707331, PMCID: PMC4529113, DOI: 10.1016/j.fertnstert.2014.12.130.Peer-Reviewed Original ResearchConceptsAntimüllerian hormone levelsAntral follicle countBody mass indexBaseline characteristicsClomiphene citrateOvarian stimulationUnexplained infertilityFollicle countHormone levelsSemen parametersMean body mass indexGood ovarian reserveMultiple Intrauterine GestationsOvarian stimulation (AMIGOS) trialUse of letrozoleComparable patient populationsProspective clinical trialsCause of infertilityOvulation induction medicationsRate of multiplesCommon baseline characteristicsNormal semen parametersBasal FSHInfertility durationBaseline demographics
2013
The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial
Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Alvero R, Casson P, Christman GM, Huang H, Yan Q, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi R, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H, Network I. The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial. Fertility And Sterility 2013, 101: 258-269.e8. PMID: 24156957, PMCID: PMC3899700, DOI: 10.1016/j.fertnstert.2013.08.056.Peer-Reviewed Original ResearchConceptsAntimüllerian hormone levelsAntral follicle countPolycystic ovary syndromeBaseline characteristicsFollicle countClinical trialsHormone levelsCross-sectional baseline dataCardiovascular risk factorsEffect of obesityMost metabolic parametersMean semen parametersFSH ratioFSH levelsII studyOvarian volumeOvary syndromeMetabolic syndromeTreatment regimensRisk factorsHealth centersMetabolic dysfunctionMetabolic parametersMAIN OUTCOMETreatment groups
1998
A Double-Blind, Placebo-Controlled, Crossover Trial of an Antiandrogen in the Treatment of Tourette's Syndrome
Peterson B, Zhang H, Anderson G, Leckman J. A Double-Blind, Placebo-Controlled, Crossover Trial of an Antiandrogen in the Treatment of Tourette's Syndrome. Journal Of Clinical Psychopharmacology 1998, 18: 324-331.. PMID: 9690699, DOI: 10.1097/00004714-199808000-00013.Peer-Reviewed Original ResearchConceptsAndrogen receptor blockadeReceptor blockadeCrossover trialHormone levelsSyndrome patientsSelective androgen receptor antagonistAdult TS subjectsTreatment of ticsTourette syndrome patientsTic symptom severitySerious side effectsAndrogen receptor antagonistSymptom severity ratingsTS prevalenceClinic visitsFlutamide administrationEndocrine findingsObsessive-compulsive disorderReceptor antagonistAndrogen receptorPhysiologic compensationTherapeutic effectPhysiologic mechanismsSide effectsTourette syndrome